Medtronic Secures FDA Approval for Breakthrough AFib Treatment with PulseSelect Pulsed Field Ablation System

Medtronic, a global leader in medical technology, has successfully obtained approval from the U.S. Food and Drug Administration (FDA) for its groundbreaking cardiac device, the PulseSelect Pulsed Field Ablation (PFA) system. This innovative technology is specifically designed to treat both paroxysmal and persistent atrial fibrillation (AFib), a prevalent irregular heartbeat condition affecting more than 6 million Americans. 

While competition in the field is fierce, with Boston Scientific Corp. and Johnson & Johnson working on similar products, Medtronic has taken the lead with the first FDA approval for an AFib-specific treatment. The approval marks a significant milestone in the race to provide an effective solution for this widespread cardiovascular condition.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

The PulseSelect PFA system employs pulsed electric fields to isolate the pulmonary veins for treatment, representing a breakthrough in AFib management. Khaldoun Tarakji, Chief Medical Officer for Medtronic Cardiac Ablation Solutions, emphasizes the system's significance, stating, "It's not just a new device. It's a new energy source." Medtronic's dedication to pulse field ablation technology spans 15 years, showcasing the company's commitment to advancing treatment options for cardiac patients.

Rebecca Seidel, President of the Cardiac Ablation Solutions business at Medtronic, highlighted the system's safety standards, stating, "Launching the first FDA-approved PFA technology is not just a milestone; the PulseSelect PFA system is setting a new standard in safety for [AFib] ablation with excellent efficacy and efficiency."

Traditional AFib treatments involve ablation, which uses heat or cold energy to create small scars in the heart, blocking faulty electrical signals and restoring a regular heartbeat. PulseSelect represents a new type of ablation that addresses some of the complications associated with traditional thermal technology.

In a global clinical trial involving 300 patients, the company recorded an impressively low adverse event rate of 0.7%, indicating a high level of safety. Moreover, over 80% of patients did not experience any recurring symptomatic atrial arrhythmias. The emphasis on safety is crucial, considering that AFib can lead to severe complications such as blood clots, heart failure, strokes, and other heart-related issues if left untreated.

Further, Paroxysmal AFib, characterized by short-term episodes, and persistent AFib, lasting longer than a week, both present significant health risks. Current treatments include medications and cardioversion procedures, but the PulseSelect PFA system offers a promising alternative.

Medtronic plans to commence sales of the PulseSelect PFA system in early 2024. The company's strategic move into the AFib treatment space was further solidified by the acquisition of Affera Inc. in 2022 for $904 million. The successful development and FDA approval of PulseSelect mark a major advancement in the company's commitment to pioneering medical technologies for cardiovascular health.